

Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 1 of 38
Prepared by: KMD, CMC	Revision 24



Letterkenny University Hospital HISTOPATHOLOGY USER MANUAL

Effective Date: 21 November 2025 Review Date: 21 November 2026

GUIDE TO USING THIS MANUAL

This User Manual has been prepared in conjunction with The Pathology Department User Manual (MP-GEN-0064) to inform the users of the Saolta University Health Care Group, Letterkenny University Hospital, Pathology Department of which services are available within the Pathology Department and how to obtain the services required.

PLEASE REFER TO DOCUMENT MP-GEN-0064, THE PATHOLOGY DEPARTMENT GENERAL USER MANUAL FOR GUIDANCE ON USING THESE DOCUMENTS.

Documents are available on Q-Pulse and also on the HSE Website http://www.hse.je/luhPatholog



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 2 of 38
Prepared by: KMD, CMC	Revision 24

Change Description:

Section	Amendment	
Page 1	Removed reference to Saolta Hospital Group	
1.1	Changed ISO15189:2012 to ISO15189:2022.	
	Added "Note: Due to an equipment upgrade, immunohistochemistry is temporarily	
	outside the scope of accreditation. This does not affect the validity of the results."	
	Changed MP-GEN-0064, Section 6 to MP-GEN-0064, Section 7.	
	Removed "relevant section of the" from the highlighted "Please note" paragraph.	
2.3	Changed MP-GEN-0064, Section 6 to MP-GEN-0064, Section 7.	
3.3	Removed "Unrefrigerated cases >24hrs old, or refrigerated samples >72hrs, will not be	
	processed."	
3.5.3	Changed testing site for BRCA from St James's Hospital to Beaumont Hospital.	
4	Added c-MYC, IDH1 R132 and FGFR2 testing to Section 4 Turnaround times	
	(Molecular Testing).	
5	Changed ISO15189:2012 to ISO15189:2022. Changed MP-GEN-0064, Section 6 to MP-	
	GEN-0064, Section 7.	
7.3.3	Removed "if a delay cannot be avoided, the sample may still be accepted if kept	
	refrigerated, up to a maximum of 72 hours."	
9.2	Removed "Unrefrigerated cases >24hrs old, or refrigerated samples >72hrs, will not be	
	processed."	
12.2.1	Removed "CMD, SJH" from BRCA appropriate test request form. Added details for c-	
	MYC, IDH1 R132 and FGFR2 requesting.	
12.2.2	Added details for c-MYC, IDH1 R132 and FGFR2 reporting.	



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 3 of 38
Prepared by: KMD, CMC	Revision 24

CONTENTS

I	INTRO	DUCTION	5
	1.2 SEF	OPE AND PURPOSE	5
2	GENER	AL INFORMATION	6
	2.2 His 2.3 Co	DICAL ADVISORY SERVICE TOPATHOLOGY STAFFING NTACT DETAILS	6 6
3	PATHO	LOGY SERVICES AVAILABLE	7
	3.2 FRC 3.3 ROI 3.4 FIN 3.5 HIS 3.5.1 3.5.2 3.5.3 3.6 TSI 3.7 ADI	UTINE HISTOPATHOLOGY DZEN SECTION UTINE NON-GYNAE CYTOLOGY E NEEDLE ASPIRATION (FNA) DTOLOGICAL/CYTOLOGICAL SAMPLES REQUIRING SPECIALIST REPORTING Renal Biopsy Muscle/Nerve Biopsy Molecular Testing E PATIENTS DITIONAL TESTING MPLES NOT EXAMINED	7 8 8 8 8
4	TURNA	ROUND TIMES	12
5	ISSUIN	G OF RESULTS	14
6	LABOR	ATORY REQUEST FORM	15
	6.2 Co	NERAL INFORMATION	15
7	SAMPL	E COLLECTION	18
	7.1.1 7.1.2 7.2 ME 7.2.1 7.2.2	ALTH & SAFETY ADVICE	18 18 18 19 20
	7.3.2	Frozen section	20
	7.3.3 7.3.4	Routine Non-Gynae Cytology	
	7.0.7	massic Dispoy	



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 4 of 38
Prepared by: KMD, CMC	Revision 24

7.3.5 Renal Biopsy (for medical diagnosis)	22
7.4 SUMMARY OF APPROPRIATE SAMPLE COLLECTION METHODS	
7.5 LABELLING THE SAMPLE CONTAINER	24
7.6 RESPONSIBILITY	
7.7 LABELLING SLIDES (APPLICABLE ONLY TO FNA REQUESTS PERFO PATHOLOGISTS)	
8 HIGH RISK SAMPLES	
9 SAMPLE QUALITY	2
9.1 SUBMISSION STATE	2 ⁻
9.2 SAMPLE TRANSPORT TIME	
9.3 UNLABELLED AND INADEQUATELY COMPLETED SAMPLES AND REG	UEST FORMS28
10 PACKAGING, DELIVERY AND TRANSPORT OF DIAGNOST SAMPLES TO THE LABORATORY	
10.1 GENERAL INFORMATION	21
10.2 SAMPLE PACKAGING	
11 STORAGE OF SAMPLES, REQUEST FORMS & REPORTS	29
12 EXTERNAL LABORATORY TESTING	3 [,]
12.1 REFERRAL FOR QUANTITATIVE ANALYSIS	3 [.]
12.2 MOLECULAR TESTING	
12.2.1 Requesting	
12.2.2 Resulting	
13 MULTI-DISCIPLINARY MEETINGS (MDM)	30
14 FURTHER EXAMINATION OF SAMPLE	
14.1 BY REPORTING PATHOLOGIST	3 ^r
14.2 BY REQUESTING CLINICIAN	
15 APPENDIX A	31



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 5 of 38
Prepared by: KMD, CMC	Revision 24

1 INTRODUCTION

1.1 Scope and purpose

This manual, in association with the Pathology Department General Information User Manual (MP-GEN-0064), is designed to provide users of the Histopathology Service at Letterkenny University Hospital with information on the proper collection and handling of primary samples destined for examination in this laboratory or referral for specialist reporting elsewhere. The Histopathology Department is concerned with the diagnosis of abnormalities within tissues and cells by microscopic examination. It is used both by hospital clinicians and General Practitioners. The Histopathology Department is an INAB-accredited laboratory (ISO15189:2022; registration number 210MT).

Note: Due to an equipment upgrade, immunohistochemistry is temporarily outside the scope of accreditation. This does not affect the validity of the results.

Please note that this manual is intended for use as a guide only; should you require any further information or clarification, please contact the Histopathology Department prior to submission of the sample (for contact details, please refer to the General Section of the User Manual (MP-GEN-0064, Section 7).

1.2 Services offered

The Histopathology Laboratory at Letterkenny University Hospital offers the following services to users:

- Routine histological examination of biopsy and resection specimens
- Frozen Section service if an urgent, intra-operative diagnosis is required
- Routine cytological examination of body fluids (including urine* but excluding cervical cytology)
- Preparation of slides (by request) and reporting of Fine Needle Aspirate (FNA) procedures (including Transbronchial FNA)
- Forwarding of muscle, nerve and renal biopsy samples for specialist histological examination and reporting
- Forwarding of samples for Molecular Testing, including Oncotype DX breast cancer assay testing

*Following discussion with the Consultant Urologist LUH, requests for urine cytology from Primary Care sources are considered inappropriate in isolation. If there is a clinical concern in relation to urological symptoms/signs, the patient should be referred for a formal urological assessment.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 6 of 38
Prepared by: KMD, CMC	Revision 24

1.3 Responsibility

The Chief Medical Scientist in charge of Histopathology is responsible for ensuring the implementation and maintenance of this procedure in conjunction with the Consultant Histopathologists.

2 GENERAL INFORMATION

2.1 Medical Advisory Service

Due to the difficulty in obtaining and often the unrepeatable nature of Histopathology/Cytology samples, users are strongly encouraged to contact an appropriate member of the Histopathology staff for advice and guidance, prior to taking the sample, if in any doubt as to the most appropriate sampling method to use.

2.2 Histopathology Staffing

The Histopathology Laboratory is staffed by:

Consultant Pathologists
Chief Medical Scientist
Senior Medical Scientist
Staff Grade Medical Scientists
Medical Laboratory Aides (MLA)
Departmental Secretaries

2.3 Contact Details

Please refer to General Section of the User manual (MP-GEN-0064), Section 7.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 7 of 38
Prepared by: KMD, CMC	Revision 24

3 PATHOLOGY SERVICES AVAILABLE

3.1 Routine Histopathology

Routine histopathological examination is performed on all biopsy samples including core biopsies, endoscopic biopsies, small resection specimens and bone marrow biopsies. It is also carried out on surgical resections removed in theatre.

3.2 Frozen Section

Frozen sections should only be requested if the immediate management of the patient is likely to be altered as a result. Requests for frozen section **MUST** always be discussed with a Consultant Pathologist. Planned frozen sections should be pre-booked with a Consultant Pathologist at least 24hrs in advance, to ensure the availability of medical and technical staff. In cases where an unplanned frozen section is required, as much warning as possible should be given to the laboratory as the equipment used requires appropriate preparation.

This service is only available between the hours of 09.00 to 16.30hrs Monday to Friday.

If the operation is delayed, or if it is subsequently found that the frozen section is not required, please notify the Histopathology Department without delay.

Hazard category 3 cases, e.g. high TB risk, known HIV, Hepatitis B or C, Covid 19 are contraindications to frozen section. If such a specimen is inadvertently processed, full decontamination of the equipment used will be required, and during this time no further frozen sections can be performed for at least 24hrs. Such instances will be recorded as clinical incidents.

3.3 Routine Non-gynae Cytology

Routine cytopathological examination is performed on all fluids (inc. urine), sputum and bronchial washings/brushings/lavages/aspirates (inc. EBUS). Any fluid aspirated/drained for cytopathological examination should **NOT** be placed in 10% formalin to allow for additional tests to be performed in the laboratory.

All fresh (unfixed) fluids **MUST** be delivered to the laboratory within the hours of 08:00 to 16:30 Monday to Friday, **AND** as promptly as possible after sample collection, to ensure cell viablity. If immediate transfer is not possible, samples should be refrigerated at 4-8°C to preserve cells. **Please note that all requests for gynaecological cytology are now handled through the National**

Please note that all requests for gynaecological cytology are now handled through the National Cervical Screening Program.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 8 of 38
Prepared by: KMD, CMC	Revision 24

3.4 Fine Needle Aspiration (FNA)

Consultant Pathologists will perform Fine Needle Aspiration (FNA) procedures **ONLY** by prior arrangement. (Please contact the department on 074 91 23579 or 074 91 24468 to book an FNA appointment).

3.5 Histological/Cytological samples requiring specialist reporting

Some histological/cytological samples received by the Histopathology Department LUH are forwarded to specialist centres for examination and reporting.

3.5.1 Renal Biopsy

Renal biopsies performed for medical diagnosis are examined and reported by the Pathology Department, Beaumont Hospital, Dublin. **The Histopathology Department LUH must be notified 5-7 days in advance of a renal biopsy for medical diagnosis being taken**. (This is to allow time to source the necessary transport medium). Biopsies from renal tumours are processed at Letterkenny University Hospital.

3.5.2 Muscle/Nerve Biopsy

Muscle/nerve biopsies for diagnosis of Neurodegenerative disorders and metabolic studies are examined and reported by the Neuropathology Department at Beaumont Hospital, Dublin.

3.5.3 Molecular Testing

Molecular Testing of archived Histopathology blocks are prepared in the Histopathology Department and sent to the relevant facility for analysis. Requests for the following molecular tests can be facilitated:



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 9 of 38
Prepared by: KMD, CMC	Revision 24

Molecular Test			Testing Location
BRCA (for PARP Inhibitor Selection)			Beaumont Hospital
Colorectal Mutation Panel			Beaumont Hospital
(KRAS, NRAS, BRAF, NTRK-1/2/3)			1
c-MYC			HSL Advanced Diagnostics, London
EGFR			Cancer Molecular Diagnostics, SJH
(T790M Mutation)			_
FGFR2			Beaumont Hospital
FoundationOne CD	Ox		Foundation Medicine Inc. (part of the
(324 genetic alteration	s)		Roche group), Germany
GIST Mutation Par	nel		Cancer Molecular Diagnostics, SJH
(KIT, PDGFRA, BRAF	V600)		G ,
Her2 ISH			Poundbury Cancer Institute, UK
IDH1 R132			Beaumont Hospital
Lung Mutation Pan	el		Beaumont Hospital
(EGFR, BRAF, KRAS,	ERBB2, PIK3CA, ALI	K, ROS1, RET,	
MET, NTRK-1/2/3)			
Melanoma Mutatio			Beaumont Hospital
(BRAF, NRAS, KIT, NT			On-site in LUH
Mis-match Repair			Beaumont Hospital
Microsatellite Insta			*
•	l		Beaumont Hospital
Oncoytpe DX			Genomic Health Inc., USA See below
PD-L1 (tumour and to		DD 11	See below
Tumour	Proposed Treatment	PD-L1 Clone	
Dragge (TNDC)			Colmon Hairramita Hamital
Breast (TNBC)	Atezolizumab	SP142	Galway University Hospital
D1 11	Pembrolizumab	22C3	Poundbury Cancer Institute
Bladder	Atezolizumab	SP142	Poundbury Cancer Institute
	Pembrolizumab	22C3	St Vincent's University Hospital
T 1	Nivolumab	28.8	Poundbury Cancer Institute
Lymphoma	Atezolizumab	SP142	Poundbury Cancer Institute
Lung	Atezolizumab	SP263	Beaumont Hospital
Melanoma	Atezolizumab	SP263	Beaumont Hospital
	Nivolumab	28.8	Poundbury Cancer Institute
Upper GI	Pembrolizumab	22C3	Poundbury Cancer Institute
	Nivolumab	28.8	Poundbury Cancer Institute
Gynae	Pembrolizumab	22C3	St Vincent's University Hospital
Head and Neck Pembrolizumab 22C3		Poundbury Cancer Institute	
TCR Gene Rearrangement			Cancer Molecular Diagnostics, SJH



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 10 of 38
Prepared by: KMD, CMC	Revision 24

(Table 1)

3.6 TSE patients

Tissue samples from patients with known or suspected new variant Creutzfeldt–Jakob disease (nvCJD), or any other Transmissible Spongiform Encephalopathy (TSE), **MUST NOT BE SENT TO THE HISTOPATHOLOGY LABORATORY AT LETTERKENNY UNIVERSITY HOSPITAL UNDER ANY CIRCUMSTANCES**. The clinical team **MUST** liaise directly with the Neuropathology Department at Beaumont Hospital, Dublin, who have the necessary facilities and expertise for dealing with such cases. They can be contacted directly on 01-8092633.

3.7 Additional Testing

Requests for specific/additional testing of already-submitted samples must be made within a certain time-limit (see Table 2 below). A Consultant Pathologist must approve all such requests. Contact the department to arrange.

Sample Type	Time Limit
Histopathology	Tissue (all embedded): no limit
	• Tissue (not all embedded): < 28 days after report
	signed out
Non-Gynae Cytology	• Unrefrigerated: must be < 24hrs old Refrigerated
	(unfixed): must be < 72hrs old
	• Refrigerated (fixed): < 7 days after report signed out
Renal Biopsy	Contact the Pathology Department, Beaumont
	Hospital for advice
	Direct Dial: 01 809 2353 or 01 809 2634
	Beaumont Ext. No.: 2353 or 2634
Muscle/Nerve Biopsy	Contact the Neuropathology Department, Beaumont
	Hospital for advice
	Direct Dial: 01 8092633
Molecular Testing	No limit

(Table 2)

3.8 Samples not examined

In the following incidences, a report will be issued with the prescibed wording:

Sample submitted	Report wording
------------------	----------------



ile MP-Histo-0005 Histopathology User Manual
age 11 of 38
levision 24
a

Cytology request on correct form BUT with no separate sample	No cytology sample received.
Cytology request on correct form BUT with inappropriate sample type	An inappropriate sample type was submitted for cytological examination. Consequently, it has not been processed and no result is available.
Urine from Primary Care	Following discussion with the Consultant Urologist LUH, requests for urine cytology from Primary Care sources are considered inappropriate in isolation. If there is a clinical concern in relation to urological symptoms/signs, the patient should be referred for a formal urological assessment.
Urine in inappropriate container	As per previous communication, urine samples for cytolgy must be collected into universal containers. Samples received in urine tubes have insufficient volume and therefore cannot be processed.
Urine with no accompanying Urine Cytology Request - Mandatory Information form	Credit sample in Histopathology, store request form in QR-722, inform Cut-up Pathologist and place urine container in fridge.
Placenta	In line with established Histopathology Specimen Acceptance Criteria, as detailed in LP-Histo-0088, this specimen has been deemed inappropriate for histopathological examination.
CSF	This specimen has been deemed inappropriate for cytological examination based on the clinical information provided.
Breast aspirates NOT performed by the Breast Care team	As per Consultant Pathologist.
Urine for fat emboli	As per Consultant Pathologist.
Sputa for PCP	As per Consultant Pathologist.

(Table 3)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 12 of 38
Prepared by: KMD, KRA	Revision 22

4 TURNAROUND TIMES

Turnaround time is defined as the number of working days from the date that the specimen/request is receipted in the Histopathology laboratory LUH until the time an authorised report is available to clinicians in LUH. The time taken for a result to be available depends on the type, size and complexity of the case.

Test	Turnaround Time
Routine Histopathology	
Small biopsy specimens	Majority (>80%) within 5 working days
• (e.g. endoscopic biopsy, core biopsy)	
Large and unfixed specimens (e.g. surgical resections)	Majority (>80%) within 7 working days
Frozen Section	Intraoperative report within 20 minutes
Non-gynae Cytology specimens inc. FNA	Majority (>80%) within 5 working days
Renal Biopsy	4-6 weeks
Muscle Biopsy	7 days
Nerve Biopsy	3-4 weeks
Molecular Testing	
BRCA	20-30 working days
Colorectal Mutation Panel	25 working days
c-MYC	10 working days
EGFR T790M Mutation	10 working days
FGFR2	20 working days
Foundation One CDx	10 working days
GIST Mutation Panel	12 working days
Her2 ISH	10 working days
IDH1 R132	20 working days
Lung Mutation Panel	21 working days
Melanoma Mutation Panel	23 working days
Mis-match Repair Analysis by IHC	4 working days
Microsatellite Instability by PCR	25 working days
MLH1 Methylation	25 working days
Oncomine Panel	20 working days
Oncotype DX	10 working days
PD-L1 Beaumont	17 working days
PD-L1 GUH	20 working days



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 13 of 38
Prepared by: KMD, KRA	Revision 22

PD-L1 Poundbury	7 working days
PD-L1 SVUH	12 working days
TCR Gene Rearrangement	13 working days
Urgent Testing	
Urgent (Histology and Non-gynae Cytology) Requests	As soon as possible. Must be discussed between Consultant Pathologist covering "cut-up" and Consultant in charge of the patient, ideally PRIOR to submitting specimen to lab. Case will not be dealt with as urgent if direct contact with a Consultant Pathologist has not been made.
	Request for urgent analysis must be used appropriately. Abuse of urgent request facility will have an adverse effect on turnaround times of genuinely urgent requests.
Urgent (Molecular Testing) Requests	Telephone Histopathology Office (07491 23579) to request that a case be flagged as urgent; this information will be relayed to the referral testing facility. Request for urgent analysis must be used appropriately. Abuse of urgent request facility will have an adverse effect on turnaround times of genuinely urgent requests.
Exceptions	

In the following situations the final report may be delayed. In such cases, an interim report **may** be issued, or the Consultant Pathologist may discuss the case with the referring doctor:

- Specimens where the tissue requires decalcification e.g. bone
- Specimens requiring lengthy and involved procedures, particularly those requiring immunohistochemistry or special stains
- Specimens where the pathologist feels a second opinion may be of benefit to the patient
- High risk specimens (Category 3)
- Staffing shortage or equipment failure

(Table 4)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 14 of 38
Prepared by: KMD, KRA	Revision 22

5 ISSUING OF RESULTS

The Department of Histopathology, Letterkenny University Hospital adheres with ISO 15189 to give assurance to users and to safeguard the quality of the results obtained. The Histopathology Department is an INAB-accredited laboratory (ISO15189:2022; registration number 210MT).

Please refer to the <u>General Information User Guide, MP-GEN-0064, Section 15.4 which</u> <u>describes the procedure in place for the reporting of Histopathology results.</u> This manual is available on Q-Pulse and the HSE website http://www.hse.ie/luhPathology

For all enquiries relating to the reporting of Histopathology/Cytology requests, please contact the Pathology Secretaries (Please refer to General User Manual MP-GEN-0064, Section 7 for contact details).



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 15 of 38
Prepared by: KMD, KRA	Revision 22

6 LABORATORY REQUEST FORM

6.1 General Information

All requests for Histological/Cytological examination must be made using the correct version of the blue, controlled Histopathology/Cytology request card (MF-0370). Supplies of these forms are available from Pathology Reception. The General Laboratory request form **MUST NOT** be used.

All requests for Urine Cytology MUST be accompanied by a fully-completed Urine Cytology Accompanying Request Form (available from the Urology Department).

Requests made on unapproved forms will not be processed.

Histopathology do NOT accept verbal requests for examinations.

The specimen type and anatomical site are particularly important in Histopathology where specimens may be multipart or left or right etc. Failure to submit essential information will result in a delay in specimen processing pending amendments being made to request forms or specimens. This may cause unnecessary delays in issuing reports.

6.2 Completing the Request Form

Note: Failure to provide the minimum data required on the Histopathology/Cytology Request form will result in a delay in processing the sample.

The following ESSENTIAL information MUST be documented, in a legible manner, on the request form. An addressograph label if available, should ideally be attached. The request form SHOULD also contain the following DESIRABLE information.

When more than one sample/specimen pot is being submitted for the same patient at the same time, the details (inc. side) of each one must be clearly stated under 'Specimen Nature/Site' i.e. A. denotes first specimen pot, B denotes second specimen pot, etc.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 16 of 38	
Prepared by: KMD, KRA	Revision 22	

= e	Histopathology
三 完	Essential Labelling Requirement:
Request Form Essential Criteria	Blue request form (RF) (active revision)
S	Hospital patients
	Three unique identifiers:
ш	1. Patient's PCN
Ξ	2. Forename & Surname
ō	3. Date of Birth
Ľ	Addressographs preferred (hand-written: must be legible)
7	Match sample labelling
<u> </u>	Match details held on LIS <u>exactly</u>
글	GP patients
ĕ	Three unique identifiers:
~	1. Forename & Surname
	2. Date of Birth
	plus one of the following:
	3. Patient's PCN
	4. Patient's Address
	Addressographs preferred (hand-written: must be legible)
	Match sample labelling
	Match details held on LIS exactly Ward/Practice Location
	Patient Consultant/GP
	MCRN or name of requesting doctor/nurse (i.e. doctor/nurse removing the tissue sample)
	Signature of Requester (i.e. doctor/nurse removing the tissue sample)
	Date of Request
	Specimen Nature/Site inc. side for each sample Clinical Details
d)	
3	Relevant clinical details should be provided; absence/inadequacy of clinical information may be noted in final report
a	noted in final report
i.	
Desirable	Patient Gender
	1 dione Gondon
	If in doubt - ask!

(Table 5)

6.3 Responsibility

Responsibility for full and correct completion of the Histopathology/Cytology request form lies solely with the requesting clinician (Hospital or GP based). Incomplete, or incorrectly completed, request forms will not be accepted under any circumstances and will not be processed until the discrepancy is amended. This, in turn, will cause a delay in sample reporting. In the event that the eligibility status of the patient is not clearly identifiable from



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 17 of 38	
Prepared by: KMD, KRA	Revision 22	

the data available/provided, it may be necessary to seek additional information from the referring Clinician prior to accepting the specimen for processing/reporting.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 18 of 38	
Prepared by: KMD, KRA	Revision 22	

7 SAMPLE COLLECTION

7.1 Health & safety advice

7.1.1 General

- Treat all biological samples as potentially-infectious and wear proper protective equipment
- Ensure that all lids are securely attached to specimen containers to minimise spillages
- Dispose of excess cytological fluid in a safe and responsible manner
- Clean up all spillages immediately and disinfect the area

7.1.2 Formalin/Formaldehyde

- Avoid skin contact as sensitisation may occur
- Always wear proper protective equipment when handling as there is a possible risk of irreversible effects
- Avoid breathing in fumes
- Ensure container is always properly labelled with formalin hazard labels

7.2 Medical indications and appropriate selection of available procedures

Certain clinical indicators will dictate the most appropriate sampling method to use when submitting tissue/fluid for histological/cytological examination. Where any doubt exists, it is advisable to contact one of the Consultant Pathologists prior to performing the procedure, who will be pleased to offer help and advice.

7.2.1 Histopathology

Sample	Clinical	Appropriate	Reason
	indicator	action/recommendation	
Skin lesion	Pigmented	Punch biopsy NOT recommended;	Risk of sampling error
		excise in full	
Lymph Node	? lymphoma	Core biopsy/FNA of lymph node	Excision-biopsy of an
		NOT recommended	entire lymph node is
			investigation of
			choice



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 19 of 38	
Prepared by: KMD, KRA	Revision 22	

Any	? malignant	Biopsy specimen recommended over	Immunocytochemistry
		cytology sample	difficult to perform on
			cytology samples and
			often gives
			unsatisfactory results

(Table 6)

7.2.2 Cytology

Sample	Clinical indicator	Appropriate action/recommendation	Reason
CSF		Routine cytological examination of CSF is inappropriate. Discuss individual case with Consultant Pathologist before taking sample	Minimal cellular yield
Breast Cyst Fluid aspirate		Do NOT submit fluid aspirated from breast cysts for cytology; refer to Breast Care North West	As per National Cancer Control Programme (NCCP) guidelines
Urine		SECOND urine sample of the day (from the beginning of the stream) collected into a sterile, white-top bottle; sample reaches Pathology Department without delay	First morning sample less suitable than other times as cells in the low pH and hypertonic environment undergo degenerative changes making cytologic assessment difficult; forward without delay to preserve cells

(Table 7)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 20 of 38	
Prepared by: KMD, KRA	Revision 22	

7.3 General information

All samples sent for histological/cytological examination **MUST** be submitted to the laboratory in the appropriate manner. Inappropriately fixed/submitted specimens have an effect on downstream patient testing and treatment decisions, therefore it is imperative that the importance of prompt and adequate tissue fixation and submission to the laboratory are not overlooked.

7.3.1 Routine Histopathology

All specimens for routine histological examination **MUST** be collected into containers of 10% neutral-buffered formalin solution. There **MUST** be sufficient formalin in the container to completely cover the specimen. The ideal ratio is 5:1 (formalin:specimen) for large samples (e.g. breast tissue, large portion of GI tract, hysterectomy, ovarian cyst, placenta) and 10:1 for small (biopsy) samples (generally any tissue smaller than a 'normal' gallbladder).

No container should be filled more than three-quarters full on health and safety grounds; select a container large enough to accommodate the tissue specimen and fixative.

Large surgical resection specimens should **NOT** be sliced or opened by the surgeon, but sent directly to the laboratory without delay.

Specimens **MUST NOT** be placed into any other solution, or into a dry container (except frozen section requests), as irreversible deterioration of the specimen will take place, making accurate microscopic interpretation impossible.

7.3.2 Frozen section

Specimens for frozen section **MUST** be placed in a suitably-sized **DRY** specimen container and transferred immediately to the Histopathology Department by hand.

Tissue for frozen section must be handed directly to a Medical Scientist or Consultant Pathologist.

7.3.3 Routine Non-Gynae Cytology

A separate sample, specifically for cytological analysis, **MUST** be submitted with the approved request form.

Requests for Cytology made on the General Laboratory request form, or without a separate sample for cytology, will not be processed.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 21 of 38	
Prepared by: KMD, KRA	Revision 22	

The method of submission of non-gynae cytology samples depends on the sample type. These samples must be forwarded to the laboratory without delay (less than 24 hours).

The main sample types are detailed below:

• **Pleural, Peritoneal and Cyst Fluids:** Up to a maximum of 25ml of fresh fluid should be sent to the laboratory in a white topped, sterile, universal container.

Drainage bags of fluid MUST NOT be sent to the laboratory. Transport of such bags poses a serious infection risk to staff and public within the hospital.

- **Sputum:** Use a white topped, sterile, universal container to collect the first deep cough specimen produced in the morning, or a sample taken after physiotherapy. The sample should be collected before breakfast or teeth cleaning. Samples comprising predominantly saliva are inadequate for cytological investigation of the lower respiratory tract. Sputum cytology should not be used as a screening investigation. It should be limited to individuals in whom a histological or cytological diagnosis is desired but in whom bronchoscopy is inappropriate or unsuccessful. Ideally, the test should be carried out on three consecutive days, with each specimen being delivered to the lab as soon as it is taken. For other suspected pathology, discuss with a Consultant Pathologist in advance.
- **Bronchial Brushings**: Collect brushings and brush tip into a 30ml Cytolyt[®] centrifuge tube (available in the Endoscopy Unit).
- **Bronchial Washings:** Collect into a 30ml Cytolyt[®] collection cup (available in the Endoscopy Unit).
- **Bronchoalveolar Lavage (BAL):** Collect into sterile, screw-top container. Do NOT add any fixative/preservative.
- **TBNA** (inc. EBUS): Collect into a 30ml Cytolyt[®] centrifuge tube (available in the Endoscopy Unit).
- **FNA** (**excluding TBNA**): Consultant Pathologists prepare FNA slides at the clinic or in the radiology department by prior arrangement, and return the sample(s) to the Histopathology laboratory for processing. Wash needle into sterile white-topped universal containing Cytolyt[®] solution (obtain from Histopathology laboratory).



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual	
Pathology Department	Page 22 of 38	
Prepared by: KMD, KRA	Revision 22	

• **Urine:** 20ml of urine in a white topped, sterile, universal container will be sufficient. For best cell yields the sample should be collected at the beginning or end of voiding urine – SECOND sample of day. It is extremely important that no alcohol or any other fixative is added to the specimen.

Note: Sample and request form MUST be accompained by a fully-completed Urine Cytology Accompanying Request Form (available from the Urology Department).

7.3.4 Muscle Biopsy

Muscle biopsy procedures **MUST** be performed as early in the day as possible to ensure that the sample is delivered to the Histopathology Laboratory LGH by 11am sharp the same day. This is to facilitate the specialist reporting centre in Dublin, who require that the biopsy arrives with them no later than 4pm on the same day. The specimen should ideally measure 15x10x10mm and be wrapped in saline dampened gauze before being placed into an empty white topped Universal container. **Do not over soak the gauze as this causes problems with ice crystal artefact formation during subsequent processing.** Make sure the specimen is reasonably loose within the container. Take care not to squash the specimen. **Do not send the sample on ice**.

Please refer to Appendix A for ward instructions on the collection of muscle biopsies.

7.3.5 Renal Biopsy (for medical diagnosis)

Two specimens should be taken: one into 10% buffered formalin and the other into Zeus fluid (transport medium). Both fixatives are available for collection by prior arrangement (5-7 days notice required) from the Histopathology Department at Letterkenny University Hospital. Renal biopsies should be received in the Histopathology Department before 11am to ensure next-day delivery to the specialist reporting centre via the laboratory courier service. The Histopathology Laboratory MUST be informed if a sample is clinically urgent so that it can be sent by taxi the same day, and the specialist centre informed.

7.4 Summary of Appropriate Sample Collection Methods

All requests, and the appropriate submission method for each, are summarised in Table 8 below:



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 23 of 38
Prepared by: KMD, KRA	Revision 22

Request	Specimen example	Appropriate submission state
Routine Histopathology	Endoscopic/core biopsy Surgical resection Bone marrow biopsy	10% Formalin (4% Formaldehyde)*
Frozen Section	Breast Colon	Dry: hand-delivered direct to lab immediately
Routine Non-gynae Cytology	Pleural fluid Sputum	Max. 25ml fresh (i.e. unfixed) in white- topped, sterile, universal container: delivered to lab without delay
	Bronchial Brushing/Washings/TBNA (inc. EBUS)	Collect into centrifuge tube/collection cup containing 30ml Cytolyt® **
	Bronchoalveolar Lavage	Collect into sterile, screw-top container. Do NOT add fixative/preservative.
	Urine	20ml Fresh (beginning or end of second morning voiding) in white-topped, sterile, universal container: delivered to lab without delay with Urine Cytology Accompanying Request Form
	FNA: Thyroid Lymph Node	Prepared by Consultant Pathologist in clinic/radiology department; wash needle into 20ml Cytolyt® ***
Muscle biopsy	Muscle biopsy Nerve biopsy	Fresh: wrapped in saline-moistened gauze (Please refer to Appendix A for ward instructions on the collection of muscle biopsies)
Renal biopsy	Renal biopsy	One sample in 10% Formalin plus one sample in Zeus Fluid***

(Table 8)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 24 of 38
Prepared by: KMD, KRA	Revision 22

^{*40}ml pre-filled, red-topped formalin pots, suitable for small biopsy samples, are available to all wards from the Pharmacy Department, Letterkenny University Hospital. Theatres acquire their own supply of formalin and specimen containers for use in the submission of large surgical resections. It is the responsibility of individual GP Surgeries to supply their own formalin and specimen containers.

- ** Sourced direct by Bronchoscopy Unit.
- *** Available direct from the Histopathology Laboratory by prior arrangement.

Please ensure that all specimen container lids are securely fastened before forwarding to the Histopathology Laboratory.

7.5 Labelling the sample container

Specimen containers MUST be labelled in such a way as to provide an unequivocal link to the patient. Best practice dictates that labelling should take place in the presence of the patient, immediately after sample collection.

The following essential information MUST be documented, in a legible manner, on the specimen container(s). An addressograph label, if available, may be used. Large sample containers MUST be labelled on the pot AND on the lid.

_	Histopathology Sample Labelling Requirement:		
<u>.a</u>			
<u> </u>	Hospital and GP patients		
<u> </u>	Two unique identifiers:		
<u> </u>	1. Forename & Surname		
0	plus one of the following:		
a	2. Patient's PCN		
Ë	3. Date of Birth		
\subseteq	Addressographs preferred (hand-written: must be legible)		
) N	Match request form labelling		
Essential Criteria			
Ш	Match details held on LIS <u>exactly</u>		
⊆			
Specimen	Specimen Nature/Site inc. side for each sample -		
Ε	when more than one sample/specimen pot is being submitted		
<u>.2</u>	for the same patient at the same time, pots should be labelled as		
Q	A. denotes first specimen pot, B denotes second specimen pot,		
<u>Q</u>	etc.		
0)	0.01		
	Exceptions:		
	•		
	Non-gynae Cytology received in sealed bag with		
	accompanying request form		
	GP skin samples received in sealed bag with accompanying		
	request form		
	 Cases with a single pot where nature of tissue is clearly 		
	evident e.g. placenta, appendix, gallbladder etc.		



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 25 of 38
Prepared by: KMD, KRA	Revision 22

If in doubt - ask!

(Table 9)

Note: Failure to provide the minimum data required on the Histopathology/Cytology sample container(s) will result in a delay in processing the sample.

7.6 Responsibility

Responsibility for full and correct labelling of any Histopathology/Cytology sample submitted to the laboratory for testing lies solely with the requesting clinician (Hospital or GP based). Unlabelled, or incorrectly labelled, samples will not be accepted under any circumstances and will not be processed until the discrepancy is amended. This, in turn, will cause a delay in sample reporting

7.7 Labelling slides (applicable only to FNA requests performed by Consultant Pathologists)

Each slide prepared, and any needle washings being submitted for examination, MUST be labelled in such a way as to provide an unequivocal link to the patient. Best practice dictates that labelling should take place in the presence of the patient, immediately after sample collection and preparation.

The following essential information MUST be documented, in a legible manner, on the slide (s) and needle washings (if applicable).

Histopathology Slide and/or Needle Washings Labelling FNA Essential Requirement: **Hospital and GP patients** Two unique identifiers: 1. Forename & Surname plus one of the following: 2. Patient's PCN 3. Date of Birth Match request form labelling Match details held on LIS exactly Number slides consecutively i.e. first slide prepared is labelled A1, second slide labelled A2, etc. If more than one area is being sampled, slides from the second area should be labelled B1, B2, etc. Needle washings should be labelled with the corresponding letter only i.e. A, B, etc. If in doubt - ask!



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 26 of 38
Prepared by: KMD, KRA	Revision 22

(*Table 10*)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 27 of 38
Prepared by: KMD, KRA	Revision 22

8 HIGH RISK SAMPLES

A "BIOHAZARD" sticker:



MUST be placed on Histopathology / Cytology sample containers **and** request forms of any specimen from a patient who is known to have, or is being investigated for, any of the following:

- Jaundice of unexplained origin
- HIV
- Hepatitis B or C
- Tuberculosis
- Viral Haemorrhagic Fever
- History of I.V. drug abuse
- Severe Acute Respiratory Syndrome (SARS)

The sample MUST undergo a minimum of 24 hours fixation before cut-up and processing.

It is desirable that the nature of the infection be stated in the clinical information section of the blue Histopathology/Cytology request form.

High risk samples, without appropriate biohazard labelling, pose a serious health and safety risk to laboratory staff; consequently, they will not be processed until a member of the clinical team attends and appropriately labels the case.

9 SAMPLE QUALITY

9.1 Submission State

Laboratory personnel inspect all samples received into the laboratory for adequate fixation (if appropriate) and/or appropriate submission state (see Table 8, Section 7.4).

9.2 Sample Transport Time

Tissue for examination by frozen section must be hand-delivered to the laboratory without delay to ensure cell viability and reportability of the sample.



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 28 of 38
Prepared by: KMD, KRA	Revision 22

Large resection specimens should be transferred to the laboratory without delay (< 60 minutes), to allow preparation of the tissue to facilitate optimal fixation.

All fresh (unfixed) fluids **MUST** be delivered to the laboratory within the hours of 08:00 to 16:30 Monday to Friday, **AND** as promptly as possible after sample collection, to ensure cell viablity. If immediate transfer is not possible, samples should be refrigerated at 4-8°C to preserve cells.

9.3 Unlabelled and inadequately completed samples and request forms

Acknowledging the unrepeatable nature of many Histopathology samples, the clinical team/GP will be given the opportunity to amend any unlabelled or inadequately completed samples or request forms. The Return of Specimen log will be completed for Hospital cases with the request pot and sample returned to source for correction/completion. Requests received from outside the Hospital will be also be returned for correction/completion.

Failure to comply with any of the submission and/or labelling requirements of the Histopathology Laboratory will result in a delay in sample processing.

Details of the discrepancy may be added to the final report.

10 PACKAGING, DELIVERY AND TRANSPORT OF DIAGNOSTIC AND INFECTIOUS SAMPLES TO THE LABORATORY

10.1 General Information

The instructions for the transport of specimens to the Laboratory are described in a separate procedure for Sample Transportation: **MP-GEN-0060**, which is available on Q-Pulse and also available on http://www.hse.ie/luhPathology

It is the responsibility of the person dispatching the specimen to the laboratory to ensure that it is packaged correctly, and does not pose a risk to anyone coming in contact with it during transport or on receipt in the laboratory.

10.2 Sample Packaging

Sample packaging is dependent on a number of factors as summarised in Table 11:



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 29 of 38
Prepared by: KMD, KRA	Revision 22

Sample being sent	Requestor Location	Method of delivery	Packaging Instruction
Biopsy (inc. frozen section) Non-gynae cytology	Within hospital	By hand	Biohazard bag, with completed request form in separate pocket
Biopsy Non-gynae cytology	Within hospital	Pneumatic chute	Bagged (individually) as for hand-delivery above and placed into pod; pad out pod if necessary
Surgical resection +/- non-gynae cytology	Within hospital	By hand	Directly into steel trolley, with completed request form
Biopsy	Out-patients (off-site)	Routine taxi transport	Bagged (individually) as for hand-delivery above, placed into dedicated transport barrel and barrel sealed (barrel returned to out-patients after samples removed)
Biopsy Non-gynae cytology	GP Surgery	Routine GP Transport	Biohazard bag, with completed request form in separate pocket

(*Table 11*)

11 STORAGE OF SAMPLES, REQUEST FORMS & REPORTS

The Histopathology department retains all specimens, blocks, slides and associated documentation in accordance with Royal College of Pathologists guidelines. Dedicated space is available for archiving tissue blocks, slides, request forms and reports. All unprocessed tissue is retained in formalin fixative in the dissection room. Non-gynae cytological samples are stored at



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 30 of 38
Prepared by: KMD, KRA	Revision 22

2-4°C in a dedicated Histopathology laboratory fridge. After the storage period, specimens are disposed of according to HSE procedure for the disposal of clinical waste.

The period of time that all histological and cytological material must be retained for is detailed in Table 12:

Item	Retention time	Storage Location
Histological Tissue Block	(Permanently) Min 30 years	Histopathology laboratory &
		store
Histological Slide	(Permanently) Min 10 years	Histopathology laboratory &
		store
Unprocessed Tissue	28 days after report issued	Histopathology laboratory
Cytological sample	7 days after report issued	Histopathology laboratory
Cytological slide	(Permanently) Min 10 years	Histopathology laboratory &
		store
Cytological block	(Permanently) Min 30 years	Histopathology laboratory &
		store
Histo/Cyto request form	Min 30 years	Histopathology office and
		electronically
Histo/Cyto report	Min 30 years	Histopathology office and
		electronically

(*Table 12*)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 31 of 38
Prepared by: KMD, KRA	Revision 22

12 EXTERNAL LABORATORY TESTING

12.1 Referral for Quantitative Analysis

Tissue from patients with equivocal Her2 results on immunocytochemistry are forwarded for quantitative analysis by *in-situ* Hybridisation (ISH) to:

Poundbury Cancer Institute (PCI)

Dorchester

UK

An addendum report will be issued by the Histopathology Department to the requesting clinician when the result of ISH testing becomes available. A copy will also be made available to the Oncology Department via a shared drive.

12.2 Molecular Testing

12.2.1 Requesting

Requests for Molecular Testing of archived Histopathology blocks must be submitted by the requesting clinician via email to Histopathology.LUH@hse.ie, and using the appropriate external request format:

Molecular Test	Appropriate request form/format
BRCA (for PARP Inhibitor Selection)	BRCA Test Request & Consent Form
	for PARP Inhibitor Selection
Colorectal Mutation Panel	Beaumont Hospital Molecular
(KRAS, NRAS, BRAF, NTRK-1/2/3)	Histopathology Test Request Form
c-MYC	HSL Advanced Diagnostics, IHC/FISH/
	Molecular Request Form
EGFR	Cancer Molecular Diagnostics, SJH
(T790M Mutation)	Request Form
FGFR2	Beaumont Hospital Molecular
	Histopathology Test Request Form
FoundationOne CDx	FoundationOne CDx online portal
(324 genetic alterations)	-
GIST Mutation Panel	Cancer Molecular Diagnostics, SJH
(KIT, PDGFRA, BRAF V600)	Request Form
IDH1 R132	Beaumont Hospital Molecular
	Histopathology Test Request Form



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 32 of 38
Prepared by: KMD, KRA	Revision 22

Lung Mutation Panel (EGFR, BRAF, KRAS, ERBB2, PIK3CA, ALK, ROS1, RET, MET, NTRK-1/2/3)			Beaumont Hospital Molecular Histopathology Test Request Form
Melanoma Mutation Panel (BRAF, NRAS, KIT, NTRK-1/2/3)		Beaumont Hospital Molecular Histopathology Test Request Form	
Mis-match Repair	Analysis (by IHC)		Beaumont Hospital Molecular Histopathology Test Request Form
Microsatellite Inst	ability (by PCR)		Beaumont Hospital Molecular Histopathology Test Request Form
MLH1 Methylatio	n		Beaumont Hospital Molecular Histopathology Test Request Form
Oncoytpe DX			Exact Sciences online portal
PD-L1 (tumour and	treatment dependent)		See below
Tumour	Proposed Treatment	PD-L1 Clone	
Breast (TNBC)	Atezolizumab	SP142	Cover letter to Dr Ann-Marie Quinn, GUH
	Pembrolizumab	22C3	Poundbury Cancer Institute Request Form
Bladder	Atezolizumab	SP142	Poundbury Cancer Institute Request Form
	Pembrolizumab	22 <i>C3</i>	SVUH PD-L1 Request Form
	Nivolumab	28.8	Poundbury Cancer Institute Request Form
Lymphoma	Atezolizumab	SP142	Poundbury Cancer Institute Request Form
Lung	Atezolizumab	SP263	Beaumont Hospital Molecular Histopathology Test Request Form
Melanoma	Atezolizumab	SP263	Beaumont Hospital Molecular Histopathology Test Request Form
	Nivolumab	28.8	Poundbury Cancer Institute Request Form
Upper GI	Pembrolizumab	22C3	Poundbury Cancer Institute Request Form
	Nivolumab	28.8	Poundbury Cancer Institute Request Form
Gynae	Pembrolizumab	22C3	SVUH PD-L1 Request Form
Head and Neck	Pembrolizumab	22C3	Poundbury Cancer Institute Request Form
TCR Gene Rearra	TCR Gene Rearrangement		Cancer Molecular Diagnostics, SJH Request Form



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 33 of 38
Prepared by: KMD, KRA	Revision 22

(*Table 13*)

12.2.2 Resulting

The Histopathology and Oncology Departments have a shared drive, available to selected staff only, to facilitate the return of molecular test results. When a new report is added to the shared drive, a notification email is sent out to inform users. All results are communicated back as shown in Table 14. Turnaround times are dependent on test(s) requested and on case complexity; indicative length of time to result are detailed in Section 4.

Molecular Test	Results
BRCA (for PARP Inhibitor Selection)	Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive
Colorectal Mutation Panel (KRAS, NRAS, BRAF, NTRK-1/2/3)	Direct to Histopathology Department via secure email; added to shared drive
c-MYC	Direct to Histopathology Department via secure email; added to shared drive
EGFR (T790M Mutation)	Direct to Consultant Oncologist, copy to Histopathology Department; added to shared drive
FGFR2	Direct to Histopathology Department via secure email; added to shared drive
FoundationOne CDx (324 genetic alterations)	Available on FoundationOne CDx online portal
GIST Mutation Panel (KIT, PDGFRA, BRAF V600)	Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive
IDH1 R132	Direct to Histopathology Department via secure email; added to shared drive
Lung Mutation Panel (EGFR, BRAF, KRAS, ERBB2, PIK3CA, ALK, ROS1, RET, MET, NTRK-1/2/3)	Direct to Histopathology Department via secure email; added to shared drive
Melanoma Mutation Panel (BRAF, NRAS, KIT, NTRK-1/2/3)	Direct to Histopathology Department via secure email; added to shared drive
Mis-match Repair Analysis (by IHC)	Addendum report issued to requesting clinician by Histopathology Department; viewable on iCM
Microsatellite Instability (by PCR)	Direct to Histopathology Department via secure email; added to shared drive
MLH1 Methylation	Direct to Histopathology Department via secure email; added to shared drive

 $\label{thm:continuous} This \ document \ is \ designed \ for \ online \ viewing. \ Printed \ copies \ not \ distributed \ by \ the \ Quality \ Manager \ are \ deemed \ \underline{UNCONTROLLED.}$



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 34 of 38
Prepared by: KMD, KRA	Revision 22

PD-L1 (tumour and treatment dependent) Tumour Proposed Treatment Clone Breast (TNBC) Pembrolizumab Bladder Pembrolizumab	Oncoytpe DX		Available on Genomic Health online	
Tumour Proposed Treatment PD-L1 Treatment Breast (TNBC) Atezolizumab SP142 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Bladder Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive Bladder Atezolizumab SP142 Direct to Histopathology Department via secure email; added to shared drive Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Lymphoma Atezolizumab SP142 Direct to Histopathology Department via secure email; added to shared drive Lung Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Melanoma Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Upper GI Pembrolizumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Upper GI Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive Upper GI Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive				portal; copy added to shared drive
Breast (TNBC) Atezolizumab Pembrolizumab Atezolizumab Bladder Atezolizumab Atezo	PD-L1 (tumour and treatment dependent)		See below	
Breast (TNBC) Atezolizumab Pembrolizumab Bladder Atezolizumab Bladder Atezolizumab Pembrolizumab Bladder Atezolizumab Pembrolizumab Atezolizumab Atezolizumab Atezolizumab Atezolizumab Atezolizumab Atezolizumab Atezolizumab Atezolizumab Lung Atezolizumab Atezoli	Tumour			
Histopathology Department; added to shared drive Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive		Treatment	Clone	
Shared drive Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive	Breast (TNBC)	Atezolizumab	SP142	
Pembrolizumab 22C3				
Secure email; added to shared drive				
Bladder Atezolizumab SP142 Direct to Histopathology Department via secure email; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; scanned to		Pembrolizumab	22C3	
Secure email; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive				secure email; added to shared drive
Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive	Bladder	Atezolizumab	SP142	Direct to Histopathology Department via
Histopathology Department; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive				secure email; added to shared drive
Shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive		Pembrolizumab	22C3	Direct to Consultant Oncologist; copy to
Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive				
Lymphoma Atezolizumab SP142 Direct to Histopathology Department via secure email; added to shared drive Lung Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Melanoma Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Melanoma Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Upper GI Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Gynae Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				shared drive
LymphomaAtezolizumabSP142Direct to Histopathology Department via secure email; added to shared driveLungAtezolizumabSP263Direct to Histopathology Department via secure email; added to shared driveMelanomaAtezolizumabSP263Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveUpper GIPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveGynaePembrolizumab22C3Direct to Consultant Oncologist; copy to Histopathology Department; added to shared driveHead and NeckPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveTCR Gene RearrangementDirect to Consultant Oncologist; copy to Histopathology Department; scanned to		Nivolumab	28.8	Direct to Histopathology Department via
Secure email; added to shared drive Lung Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Melanoma Atezolizumab SP263 Direct to Histopathology Department via secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Upper GI Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Oirect to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				secure email; added to shared drive
LungAtezolizumabSP263Direct to Histopathology Department via secure email; added to shared driveMelanomaAtezolizumabSP263Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveUpper GIPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveGynaePembrolizumab22C3Direct to Consultant Oncologist; copy to Histopathology Department; added to shared driveHead and NeckPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveTCR Gene RearrangementDirect to Consultant Oncologist; copy to Histopathology Department; scanned to	Lymphoma	Atezolizumab	SP142	Direct to Histopathology Department via
Secure email; added to shared drive				secure email; added to shared drive
MelanomaAtezolizumabSP263Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveUpper GIPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveGynaePembrolizumab22C3Direct to Consultant Oncologist; copy to Histopathology Department; added to shared driveHead and NeckPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveTCR Gene RearrangementDirect to Consultant Oncologist; copy to Histopathology Department; scanned to	Lung	Atezolizumab	SP263	Direct to Histopathology Department via
Secure email; added to shared drive				secure email; added to shared drive
Nivolumab28.8Direct to Histopathology Department via secure email; added to shared driveUpper GIPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveNivolumab28.8Direct to Histopathology Department via secure email; added to shared driveGynaePembrolizumab22C3Direct to Consultant Oncologist; copy to Histopathology Department; added to shared driveHead and NeckPembrolizumab22C3Direct to Histopathology Department via secure email; added to shared driveTCR Gene RearrangementDirect to Consultant Oncologist; copy to Histopathology Department; scanned to	Melanoma	Atezolizumab	SP263	1 0, 1
Secure email; added to shared drive Upper GI Pembrolizumab Nivolumab Secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Organe Pembrolizumab Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				secure email; added to shared drive
Upper GI Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Gynae Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to		Nivolumab	28.8	Direct to Histopathology Department via
secure email; added to shared drive Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Gynae Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				secure email; added to shared drive
Nivolumab 28.8 Direct to Histopathology Department via secure email; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to	Upper GI	Pembrolizumab	22C3	
Secure email; added to shared drive Gynae Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				
Gynae Pembrolizumab 22C3 Direct to Consultant Oncologist; copy to Histopathology Department; added to shared drive Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to		Nivolumab	28.8	1 65 1
Head and Neck Pembrolizumab TCR Gene Rearrangement Histopathology Department; added to shared drive Direct to Histopathology Department via secure email; added to shared drive Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				,
Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to	Gynae	Pembrolizumab	22C3	Direct to Consultant Oncologist; copy to
Head and Neck Pembrolizumab 22C3 Direct to Histopathology Department via secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				Histopathology Department; added to
secure email; added to shared drive TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to				shared drive
TCR Gene Rearrangement Direct to Consultant Oncologist; copy to Histopathology Department; scanned to	Head and Neck	Pembrolizumab	22C3	Direct to Histopathology Department via
Histopathology Department; scanned to				secure email; added to shared drive
	TCR Gene Rearra	ngement		
iCM				
L				iCM

(*Table 14*)



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 35 of 38
Prepared by: KMD, KRA	Revision 22



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 36 of 38
Prepared by: KMD, KRA	Revision 22

13 MULTI-DISCIPLINARY MEETINGS (MDM)

Consultant Pathologists from the Histopathology Department attend regular multi-disciplinary meetings (MDMs) to discuss individual cases. Also present at these meetings are members of surgical, radiological, oncological and nursing staff from within Letterkenny University Hospital, as well as staff from specialist centres via video-conferencing. The schedule is as follows:

MDM	Frequency
Gynae	Weekly (Tuesday)
Breast	Weekly (Thursday)
GI	Weekly (Friday)
Endocrine	Fortnightly (Monday)
Colposcopy	Monthly (Tuesday)
Inflammatory GI	Monthly (Friday)

(*Table 15*)

Slides will be referred to outside institutions for MDM discussion at the request of the clinical team, and upon completion of MF-0399 Request for Pathology Material Review (Histopathology/Cytology).



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 37 of 38
Prepared by: KMD, KRA	Revision 22

14 FURTHER EXAMINATION OF SAMPLE

14.1 By Reporting Pathologist

Consultant Pathology staff may refer cases to colleagues, both on-site and elsewhere, when they feel that a second opinion or further stains may be of benefit to the patient. All cases of equivocal Her2 results will also be referred for quantitative Her2 analysis by *in-situ* Hybridization (ISH). In any such instance, a final report will be issued, with an addendum report following once all investigations are complete.

14.2 By Requesting Clinician

All requests for further examination of the primary sample **MUST** be made directly to the reporting Primary Pathologist by the Consultant in charge of the patient and on completion of the appropriate request form (MF-0399 Request for Pathology Material Review (Histopathology/Cytology).



Letterkenny University Hospital	File MP-Histo-0005 Histopathology User Manual
Pathology Department	Page 38 of 38
Prepared by: KMD, KRA	Revision 22

15 APPENDIX A

Ward Information for collection of Muscle Biopsies

- 1. Muscle biopsies should be performed as early in the morning as possible as they must arrive at the Beaumont Hospital in Dublin before 4.00pm.
- 2. Check that both specimen containers and request form are correctly labelled.
- **3.** The specimen should ideally measure 15x10x10mm.
- 4. Wrap the specimen in saline dampened gauze and place into an empty white topped Universal container. Do not over soak the gauze as this causes problems with ice crystal artefact formation during subsequent processing.
- **5.** Make sure the wrapped specimen is reasonably loose within the container. **Take care not to squash the specimen.**
- 6. Do not send the samples on ice.
- 7. Send the sample to the Histopathology Department at Letterkenny University Hospital, to arrive by 11:00am at the latest.